STOCK TITAN

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that Dr. Helen Sabzevari, President and CEO, will engage in a virtual fireside chat at the 2022 H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 AM ET. Interested participants can register for the webcast via Precigen's website. The company focuses on innovative gene and cell therapies targeting serious diseases, including immuno-oncology, autoimmune disorders, and infectious diseases. For more details, visit their official site.

Positive
  • None.
Negative
  • None.

GERMANTOWN, Md., May 17, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the 2022 H.C. Wainwright Global Investment Conference. A webcast of the event will be available beginning at 7:00 AM ET on Tuesday, May 24, 2022.

Participants may register and access the webcast through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com

Media Contacts:
Donelle M. Gregory
press@precigen.com

Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-2022-hc-wainwright-global-investment-conference-301549528.html

SOURCE Precigen, Inc.

FAQ

When will Precigen participate in the 2022 H.C. Wainwright Global Investment Conference?

Precigen will participate in the conference on May 24, 2022.

Who is speaking for Precigen at the H.C. Wainwright Global Investment Conference?

Dr. Helen Sabzevari, President and CEO of Precigen, will be speaking.

What time does Precigen's presentation start at the conference?

The presentation starts at 7:00 AM ET.

Where can I access the webcast for Precigen's participation in the conference?

The webcast can be accessed through Precigen's website in the Events & Presentations section.

What is the focus of Precigen's therapies?

Precigen specializes in gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.

Precigen, Inc.

NASDAQ:PGEN

PGEN Rankings

PGEN Latest News

PGEN Stock Data

219.42M
263.81M
10.17%
63.83%
5.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GERMANTOWN